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Abstract
Background: Recent evidence suggests that neutrophil gelatinase-associated lipocalin (NGAL)
expression is induced in many types of human cancer, while detection of its complex with matrix
metalloproteinase-9 (MMP-9) is correlated with cancer disease status. We aim to evaluate the
serum expression of MMP-9, NGAL and their complex (MMP-9/NGAL) during the diagnostic
work-up of women with breast abnormalities and investigate their correlation with disease
severity.
Methods: The study included 113 women with non-palpable breast lesions undergoing vacuum-
assisted breast biopsy for histological diagnosis, and 30 healthy women, which served as controls.
Expression levels of MMP-9, NGAL and their complex MMP-9/NGAL were determined in
peripheral blood samples with immunoenzymatic assays.
Results: Women with invasive ductal carcinoma exhibited significantly increased levels of MMP-9,
NGAL and MMP-9/NGAL compared to healthy controls (MMP-9: p < 0.003, NGAL: p < 0.008
MMP-9/NGAL: p < 0.01). Significant correlations were observed between MMP-9 and NGAL
serum levels and breast disease severity score (r = 0.229, p < 0.006 and r = 0.206, p < 0.01,
respectively), whereas a non-significant correlation was found for their complex. MMP-9, NGAL
and their complex MMP-9/NGAL levels were not correlated with either Body Mass Index (BMI) or
age of patients.
Conclusion: These findings suggest that the serum measurement of MMP-9 and NGAL may be
useful in non-invasively monitoring breast cancer progression, while supporting their potential role
as early biomarkers of breast disease status.
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Background
The lipocalins constitute a family of small-secreted pro-
teins capable of binding hydrophobic molecules. Their
principal function is the transport of lipophilic substances
but they also participate in immunomodulation and syn-
thesis of prostaglandins [1]. Lipocalin 2 or neutrophil
gelatinase-associated lipocalin (NGAL) is a prominent
member of the lipocalin family and was originally identi-
fied as a glycoprotein in complex with matrix metallopro-
teinase-9 (MMP-9) in human neutrophils [2,3].
NGAL is an acute phase protein and its expression is
upregulated under diverse conditions [4,5]. It has been
extensively investigated as a biomarker for the early diag-
nosis of acute kidney injury from diverse etiologies [6-9].
Recent evidence suggests that NGAL expression is induced
in many types of human cancer, including breast [10,11],
gastric [12], esophageal squamous cell [13], colorectal [5],
pancreatic [14,15], lung [16] and ovarian cancer [17].
Regarding breast cancer, Stoesz and coworkers originally
reported heterogeneous expression of NGAL mRNA and
protein levels in breast cancer tissue that significantly cor-
related with other markers of poor prognosis including
estrogen and progesterone receptor-negative status and
high proliferation [10]. Bauer et al recently extended these
findings to show that immunohistochemical NGAL
expression strongly correlated with negative steroid recep-
tor status, Her-2/neu overexpression, poor histologic
grade, the presence of lymph node metastasis and high
proliferation index. In univariate analysis, NGAL expres-
sion was associated with decreased disease-specific and
disease-free survival. In multivariate analysis, NGAL
remained an independent prognostic marker for disease-
free survival. These data suggested that tissue NGAL
expression could be a valuable prognostic marker in
patients with primary breast cancer [11]. Gene expression
profiling studies have also confirmed the correlation
between NGAL expression and negative estrogen receptor
status [18-21].
It has been established that NGAL forms a complex with
matrix metalloproteinase-9, thereby preventing MMP-9
autodegradation and increasing its activity in vitro [22].
MMP-9 plays a critical role in cancer progression, invasion
and metastasis in several neoplastic diseases including
breast cancer [23]. Since MMP-9 is implicated in both
early and late processes of tumor progression through the
degradation of the extracellular matrix and basement
membranes [24], the question whether NGAL and MMP-
9/NGAL complex contributes to tumor progression was
raised.
Fernandez et al investigated the role of MMP-9/NGAL
complex in breast tumor growth and its presence in the
urine of breast cancer patients [25]. Their findings sug-
gested that detection of urinary MMP-9/NGAL complex
might represent an independent predictor of disease sta-
tus. Recently, Smith and coworkers reported significant
elevations in MMP-9 and MMP-9/NGAL in brain tumor
patients. Their expression correlated with the presence of
disease and the response to therapy and could be detected
both in tumor tissue and urine samples [26]. An associa-
tion between MMP-9/NGAL complex and gastric cancer
has also been suggested since complex expression in
tumor tissue of gastric cancer patients was highly associ-
ated with worse survival and was related to the histologi-
cal and genetic typing of gastric cancer [12]. Moreover,
recent studies have suggested an association between
MMP-9/NGAL complex expression and abdominal aortic
aneurysms as well as osteoarthitis [27,28].
To date, most studies have focused on NGAL and MMP-9/
NGAL tissue expression while only a few have investigated
the clinical utility of their urinary measurements. NGAL
and MMP-9 are stored in specific granules in neutrophils,
while MMP-9 is also found in gelatinase granules. They
both mainly exist in forms not associated with each other.
Due to its large size, it seems unlikely that the MMP-9/
NGAL complex can be directly filtered from serum to
urine. It has thus been suggested that MMP-9 and NGAL
are mainly secreted in blood by neutrophils infiltrating
the tumor, and are separately excreted in urine where they
subsequently form complexes [22]. Although the detec-
tion of NGAL and its complex with MMP-9 in systemic cir-
culation seems reasonable, no studies of NGAL and MMP-
9/NGAL in sera are currently available with the exception
of two recent publications on coronary artery disease and
polycystic ovary syndrome [29,30]. The aim of our study
is to evaluate the serum levels of MMP-9, NGAL and
MMP-9/NGAL complex in patients with breast abnormal-
ities and investigate their correlation with breast disease
severity.
Methods
The study included 113 women; 35 with sclerosing ade-
nosis, 18 with atypical ductal hyperplasia (ADH), 32 with
ductal carcinoma in situ (DCIS), and 28 with invasive
breast cancer (IDC), while 30 healthy women served as
controls. The mean age of the patients and controls was
52.8 ± 9.7 and 55.0 ± 13.7 years, respectively, whereas
their Body Mass Index (BMI) was 26.2 ± 4.7 and 25.9 ± 4.4
kg/m2, respectively. Prior to their enrollment, all the par-
ticipants were evaluated for the absence of metabolic dis-
orders including diabetes, diagnosed inflammatory
disease and abnormal liver and kidney function. Healthy
controls were confirmed after clinical examination, mam-
mography and serological analysis during their annual
breast screening. Peripheral blood samples were obtained
from patients before preoperative histological diagnosis
of non-palpable lesions by vacuum-assisted breast biopsyBMC Cancer 2009, 9:390 http://www.biomedcentral.com/1471-2407/9/390
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(VABB), after overnight fasting. The histopathological
data were reported during the statistical analysis, after the
blind completion of the assays. Based on the published
relative risk of breast benign diseases for cancer, the
women were classified into five groups of increasing
severity as follows: Healthy controls = Disease Severity
Score 1; Sclerosing Adenosis = Disease Severity Score 2;
Atypical Ductal Hyperplasia = Disease Severity Score 3;
Ductal Carcinoma In Situ = Disease Severity Score 4 and
Invasive Breast Cancer = Disease Severity Score 5. The par-
ticipants were recruited from the Breast Unit, First Depart-
ment of Propaedeutic Surgery, Athens University Medical
School at Hippokratio Hospital between September 2005
and June 2007. The protocol was approved from the Insti-
tutional Research Committee and written informed con-
sent was obtained from each patient prior to study entry.
Sample Collection and Assays
Peripheral venous blood samples were collected between
12:00 a.m. and 14:00 p.m. into separator vacutainers and
allowed to clot for 20 to 30 min at room temperature. The
samples were centrifuged at 3000 × g for 15 min at 8°C,
divided into aliquots and stored at -80°C until being
assayed. The determination of serum MMP-9 concentra-
tions was performed in duplicates, on the Luminex-100 IS
(Integrated System) Luminex Corporation, Austin, TX, US
using the MMP-9 assay kit manufactured by R&D Systems,
Minneapolis, MN, US. Multianalyte profiling calibration
microspheres for classification and reporter readings, as
well as sheath fluid were purchased from Luminex Corpo-
ration. The acquired fluorescence data were analyzed with
the Luminex 2.3 Version software. All analyses were per-
formed according to the manufacturers' protocols. Serum
NGAL and MMP-9/NGAL levels were determined in
duplicate by solid phase ELISA techniques (R&D Systems,
Minneapolis, MN, US). According to manufacturers, the
intra-assay and inter-assay CVs for NGAL range between
3.1 and 4.1% and 5.6 and 7.9%, respectively, and for
MMP-9/NGAL range between 2.3 and 4.1% and 5.1 and
7.6%, respectively.
Statistical Analysis
Data are expressed as mean ± SD. Comparison of analytes
within groups was performed using the Student t-test. The
correlation coefficient r  between the parameters tested
was computed using least squares regression analysis. The
p values reported are two tailed. All the statistical proce-
dures were performed using the STATGRAFICS 5.1 for
Windows program (Graphic Software System, STAT-
POINT TECHNOLOGIES, INC. Warrenton, Virginia, US).
Results
Benign breast diseases, encompassing atypical ductal
hyperplasia and sclerosing adenosis, have been associated
with varying relative risk for developing cancer for
patients with no family history, depending on their histo-
logical features [31]. Based on these data, we classified our
patients into five groups of increasing disease severity and
we evaluated the correlation between the expression of
MMP-9, NGAL, and MMP-9/NGAL complex and severity
score. Mean serum levels of MMP-9, NGAL and MMP-9/
NGAL complex in healthy women and patients with scle-
rosing adenosis, ADH, DCIS and IDC are presented in
Table 1. Patients with invasive carcinoma exhibited signif-
icantly increased levels of all three molecules compared to
healthy controls (MMP-9: p < 0.003, NGAL: p < 0.008
MMP-9/NGAL: p < 0.01).
Increased MMP-9 serum levels were observed for all
patients compared to healthy subjects (Figure 1). It is
noteworthy that women with sclerosing adenosis exhib-
ited significantly elevated MMP-9 expression, similar to
that observed for invasive carcinoma (Table 1). A signifi-
cant positive correlation was observed between MMP-9
serum levels and disease severity score (r = 0.229, p <
0.006). Regarding NGAL, increased serum expression was
observed for patients with breast disease compared to
healthy controls (Figure 2). NGAL serum levels were sim-
ilar between women with DCIS, ADH and sclerosing ade-
nosis whereas a marked increase was observed for women
with invasive carcinoma (Table 1). A significant positive
correlation between NGAL serum levels and disease sever-
ity score was found (r = 0.206, p < 0.02). Higher serum
levels of MMP-9/NGAL were observed in IDC, DCIS, ADH
and sclerosing adenosis patients compared to healthy
women (Figure 3). Increased expression was mainly
observed for patients with invasive carcinoma, whereas
DCIS, ADH and sclerosing adenosis patients exhibited
Table 1: Serum levels of MMP-9, NGAL and MMP-9/NGAL complex.
Healthy Controls
(N = 30)
Sclerosing Adenosis
(N = 35)
ADH
(N = 18)
DCIS
(N = 32)
IDC
(N = 28)
NGAL (ng/ml) 70.7 ± 17.4 78.3 ± 28.8 79.1 ± 30.6 80.0 ± 22.5 87.4 ± 28.1*
MMP-9 (ng/ml) 264.2 ± 128.3 402.0 ± 284.8 326.0 ± 171.8 330.7 ± 165.7 392.6 ± 181.7**
MMP-9/NGAL (ng/ml) 39.9 ± 20.9 54.9 ± 41.0 53.9 ± 36.7 49.5 ± 34.1 60.7 ± 42.3***
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia 
(ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC). Data are expressed as mean ± SD. Significantly increased expression 
is observed for patients with IDC compared to healthy controls (*NGAL: p < 0.008, **MMP-9: p < 0.003, ***MMP-9/NGAL: p < 0.01).BMC Cancer 2009, 9:390 http://www.biomedcentral.com/1471-2407/9/390
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similar expression levels (Table 1). A positive non-signifi-
cant correlation was found between MMP-9/NGAL com-
plex expression and disease severity score (r = 0.123, p >
0.14). MMP-9, NGAL and MMP-9/NGAL complex serum
levels were not significantly correlated with either age or
BMI of patients (p > 0.1).
Discussion
NGAL appears to protect MMP-9 from autodegradation,
increasing its activity by binding and forming MMP-9/
NGAL complexes. Tumor cells excrete elevated levels of
NGAL resulting in an increase in local concentration of
MMP-9, which can affect various aspects of tumor pro-
gression [22]. NGAL is abundantly expressed in adipose
tissue and liver and recent studies have correlated circulat-
ing NGAL levels with obesity and its metabolic complica-
tions [32,33]. NGAL has also been suggested as a marker
of acute kidney injury [6-9]. Therefore normal liver and
renal function was clinically confirmed for all patients
included in this study prior to their enrollment. Moreover,
no patients with metabolic syndromes participated in the
study. According to our findings, serum levels of MMP-9,
NGAL, and MMP-9/NGAL were not associated with obes-
ity since no correlation with patients' BMI was observed.
Immunohistochemical studies on breast tissue have asso-
ciated MMP-9 expression with a higher rate of distant
metastases [34-36]. The prevention of the metastatic proc-
ess is the main aim of the clinicians. Soluble biomarkers
could be useful tools in the prediction of patient outcome
and management of the disease. Therefore, MMP-9 detec-
tion in sera could provide significant information of the
tumor biological features. Somiari and coworkers have
suggested that circulating MMP-2 and MMP-9 levels are
associated with disease severity and may permit the classi-
fication of patients with breast disease [24,37]. These find-
ings were recently extended from Wu et al, who reported
that serum MMP-9 levels were significantly elevated in
patients with breast cancer compared to those with benign
breast disease and healthy controls. Additionally,
increased MMP-9 levels were associated with lymph node
metastasis, higher tumor stage, lower relapse-free and
overall survival [36]. In agreement with these observa-
tions, our study reported an increase in MMP-9 expression
Serum levels of MMP-9 depicted as box-plots Figure 1
Serum levels of MMP-9 depicted as box-plots. (Boxes 
represent the interquartile range; lines inside boxes repre-
sent the median value; whiskers represent 5th and 95th per-
centiles). The 1-5 scale represents breast abnormalities of 
increasing severity as follows: 1: Healthy controls (N = 30), 
2: Sclerosing adenosis (N = 35), 3: Atypical ductal hyperplasia 
(ADH) (N = 18), 4: Ductal carcinoma in situ (DCIS) (N = 32) 
and 5: Invasive ductal carcinoma (IDC) (N = 28).
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Serum levels of NGAL depicted as box-plots Figure 2
Serum levels of NGAL depicted as box-plots. (Boxes 
represent the interquartile range; lines inside boxes repre-
sent the median value; whiskers represent 5th and 95th per-
centiles). The 1-5 scale represents breast abnormalities of 
increasing severity as follows: 1: Healthy controls (N = 30), 
2: Sclerosing adenosis (N = 35), 3: Atypical ductal hyperplasia 
(ADH) (N = 18), 4: Ductal carcinoma in situ (DCIS) (N = 32) 
and 5: Invasive ductal carcinoma (IDC) (N = 28).
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in patients with ADH, DCIS and IDC (p < 0.003) com-
pared to healthy controls. Our results also document a
positive correlation between MMP-9 serum levels and the
severity score of breast disease (p < 0.006).
Recent evidence suggests that NGAL expression is associ-
ated with cancer invasive progression. Gene expression
profiling and analysis of human pancreatic adenocarcino-
mas by cDNA microarrays, quantitative real-time RT-PCR
and immunohistochemistry demonstrated increased
expression of NGAL in malignant pancreatic tissue com-
pared to normal [38]. Lim et al reported that tissue expres-
sion of NGAL in ovarian tumors changes with disease
grade and this is also reflected in serum levels [17]. More
specifically, tissue NGAL expression was undetectable in
normal ovaries, weak to moderate in benign tissues, while
it displayed highest levels in borderline and low-grade
tumors. The authors also reported similar findings for
NGAL expression in serum, with levels being significantly
higher in patients with benign and grade 1 tumors com-
pared to healthy controls. The role of NGAL was also
investigated in esophageal squamous cell carcinoma
(ESCC) and it was reported that its tissue expression was
significantly higher in ESCC than in normal mucosa, and
was positively correlated with cell differentiation [13].
Based on their findings that NGAL in human tissue and
urine samples were consistently associated with invasive
breast cancer, Yang et al suggested that NGAL may be a
potential noninvasive biomarker of breast disease [39].
Our findings further support the hypothesis that NGAL is
associated with cancer disease severity. Serum NGAL lev-
els were higher in patients with IDC (p < 0.008) while
moderate in patients with DCIS, ADH and sclerosing ade-
nosis compared to healthy controls. A significant positive
correlation between NGAL expression and breast disease
severity score was also observed (p < 0.02).
Regarding MMP-9/NGAL, current evidence suggests that
urinary detection of the complex may represent a new
biomarker for the prediction of cancer disease [25,26].
NGAL overexpression in human breast cancer cell lines
was accompanied by increased tumor growth, MMP-9
activity, angiogenesis and cell proliferation. Moreover,
MMP-9/NGAL enzymatic activity was observed in the
urine of breast cancer patients but not in healthy controls
[25]. Evaluation of MMP-9 and MMP-9/NGAL complex in
urine of patients with brain tumors revealed significantly
higher expression levels compared to controls, which was
also confirmed in tumor tissue. After tumor resection,
clearing of biomarkers was observed. The findings support
an association between MMP-9 and MMP-9/NGAL urine
levels with the presence of disease and response to therapy
[26]. In our study, we attempted to evaluate the expres-
sion of MMP-9/NGAL complex in serum of patients with
breast disease and correlate it with disease severity.
Despite observing higher levels of MMP-9/NGAL in IDC
(p < 0.01), DCIS, ADH and sclerosing adenosis patients
compared to healthy controls, a positive non-significant
correlation between complex expression and disease
severity score was found. However, future studies includ-
ing a higher number of patients could elucidate the signif-
icance of serum MMP-9/NGAL expression in patients with
breast disease.
The relation between breast benign diseases and invasive
cancer has been a matter of discussion for many years, as
these lesions are considered precursors in malignant
transformation. Sclerosing adenosis is a benign prolifera-
tive lesion without atypia with a relative risk for malignant
breast disease of 1.3-1.9, while ADH has a slightly higher
risk (× 3.9-5.0) [31]. Since sclerosing adenosis and ADH
are believed to constitute distinct precursors of invasive
breast carcinoma, we attempted to investigate potential
differences in the tested parameters. Higher levels of
NGAL and MMP-9/NGAL complex were observed for
both groups of patients compared to healthy controls,
whereas MMP-9 expression was particularly elevated in
Serum levels of MMP-9/NGAL complex depicted as box- plots Figure 3
Serum levels of MMP-9/NGAL complex depicted as 
box-plots. (Boxes represent the interquartile range; lines 
inside boxes represent the median value; whiskers represent 
5th and 95th percentiles). The 1-5 scale represents breast 
abnormalities of increasing severity as follows: 1: Healthy 
controls (N = 30), 2: Sclerosing adenosis (N = 35), 3: Atypi-
cal ductal hyperplasia (ADH) (N = 18), 4: Ductal carcinoma 
in situ (DCIS) (N = 32) and 5: Invasive ductal carcinoma 
(IDC) (N = 28).
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the sclerosing adenosis group. This observation seems to
support the idea that this lesion is a distinct entity of
benign disease. Whether serum levels of MMP-9, NGAL
and their complex can reflect the relative risk of patients
with benign diseases for developing breast cancer remains
to be investigated in future studies.
Improved non-operative diagnostic techniques enable the
detection of breast cancer at an earlier stage. At the same
time, serum measurements represent a non-invasive, eas-
ily accessible method for the study of biomarkers as
screening tools for risk assessment, diagnosis and progno-
sis of breast cancer. The present study was designed in an
effort to reveal specific biomarkers associated with breast
disease progression. Our data suggest that MMP-9 and
NGAL are positively correlated with breast disease sever-
ity, with a potential clinical utility as early markers of
breast disease status.
Conclusion
In spite of the supporting evidence in the literature, the
significance of circulating MMP-9 in prognosis and pro-
gression of breast cancer disease requires further clarifica-
tion. On the other hand, NGAL and MMP-9/NGAL
complex have not yet been evaluated in breast cancer.
Even though the detection of NGAL and MMP-9/NGAL
complex in systemic circulation is likely to directly reflect
their tissue expression, scarce data are currently available
on the significance of their serum measurement in cancer
disease. To our knowledge, this is the first study attempt-
ing to investigate the serum expression of MMP-9, NGAL
and MMP-9/NGAL complex during diagnostic work-up of
patients with breast abnormalities and correlate it with
the severity of the disease. Our findings suggest that both
MMP-9 and NGAL serum levels are correlated with breast
cancer progression since they seem to follow a gradual
increase with disease severity, supporting their potential
role as early biomarkers.
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